Sec. 404. Reauthorization; reporting requirements
243 words·~1 min read·
/bill/117/hr/7667/eh/section-404·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 744I of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–53 ) is amended— in subsection (a)(1), by striking Beginning with fiscal year 2018, not and inserting Not ; by striking Biosimilar User Fee Amendments of 2017 each place it appears and inserting ; Biosimilar User Fee Amendments of 2022 in subsection (a)(2), by striking Beginning with fiscal year 2018, the and inserting The ; in subsection (a)(3)(A), by striking Not later than 30 calendar days after the end of the second quarter of fiscal year 2018, and not later than 30 calendar days after the end of each quarter of each fiscal year thereafter and inserting Not later than 30 calendar days after the end of each quarter of each fiscal year for which fees are collected under this part ; in subsection (b), by striking Not later than 120 days after the end of fiscal year 2018 and each subsequent fiscal year for which fees are collected under this part and inserting Not later than 120 days after the end of each fiscal year for which fees are collected under this part ; in subsection (c), by striking Beginning with fiscal year 2018, and for and inserting For ; and in subsection (f)— in paragraph (1), in the matter preceding subparagraph (A), by striking fiscal year 2022 and inserting fiscal year 2027 ; and in paragraph (3), by striking January 15, 2022 and inserting January 15, 2027 .
Connections1 off-index
1 reference not yet in our index
- 21 USC 379j–53
Citation graph
cites case law
Sec. 404
Reauthorization; reporting requirements
Cite21 USC 379j–53
Cites 1Cited by 0 across 0 sources